XOMA to Announce 2009 and Fourth Quarter Financial Results and Host Conference Call on March 11 Mar 04, 2010 5:02pm EST
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients Feb 09, 2010 7:00am EST
XOMA Announces $21 Million Underwritten Offering of Common Shares and Warrants Feb 02, 2010 8:45am EST
XOMA Presents Advantages of Its Multiple Antibody Formulation Technologies at Antibody Engineering Conference Dec 10, 2009 9:00am EST
